# US 2020/0270636 A1 · Closed-ended, linear, duplex adenoassociated virus dna, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270636 A1
- Document ID: US20200270636A1
- Status: Published application
- Kind: A1
- Application number: 16/637,152
- Filed: 2017-08-09
- Published: 2020-08-27
- Earliest claimed: 2017-08-09
- Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services
- Applicants: The USA, AS Represented By the Secretary, Dept. of Health and Human Services
- Inventors: Lina LI; Robert KOTIN
- Web page: https://patentgrep.com/patent/US20200270636A1

## CPC

- C12N 15/86: Viral vectors
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2310/532: Closed or circular
- C12N 2750/14123: Virus like particles [VLP]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Closed-ended, linear, duplex (CELID) DNA molecules, recombinant AAV (rAAV), particles comprising CELID DNA, methods of making such molecules and particles, and therapeutic applications of such particles.

## Claims

### Claim 1

A method of producing a recombinant AAV (rAAV) particle comprising heterologous DNA, the method comprising culturing a cell comprising:
i) closed ended, linear duplex (CELiD) DNA comprising the heterologous DNA; and,
ii) one or more nucleic acid molecules encoding one or more AAV capsid (Cap) proteins;
under conditions suitable for formation of AAV particles containing the CELID DNA.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more nucleic acid molecule(s) is/are stably inserted into the genome of the cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cultured cell comprises one or more polynucleotide molecules encoding one or more AAV Rep proteins, and wherein the culture conditions comprise a culture environment suitable for replication of the CELID DNA, expression of the one or more Cap proteins, and expression of the one or more Rep proteins.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cell is an invertebrate cell or a mammalian cell.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein the heterologous DNA encodes a protein or a therapeutic RNA.

### Claim 7 (depends on 6)

The method of claim 6, wherein the therapeutic RNA comprises a siRNA, a RNAi, a shRNA, a miRNA, an aptamer, or a ribozyme.

### Claim 8 (depends on 1)

A recombinant AAV (rAAV) particle produced by the method of claim 1.

### Claim 9 (depends on 8)

A kit comprising the rAAV particle of claim 8.

### Claim 10 (depends on 8)

A method of protecting an individual against a disease, comprising administering the rAAV particle of claim 8 to the individual, wherein the rAAV particle comprises heterologous DNA encoding a therapeutic molecule that protects the individual against the disease.

### Claim 11 (depends on 8)

A method of treating an individual for an illness, comprising administering the rAAV particle of claim 8 to the individual, wherein the rAAV particle comprises heterologous DNA encoding a therapeutic molecule that treats the illness.

### Claim 12 (depends on 8)

A method of eliciting an immune response in an individual, comprising administering the rAAV particle of claim 8 to the individual, wherein the rAAV particle comprises heterologous DNA encoding an immunogenic protein.

### Claim 13

A recombinant AAV (rAAV) particle comprising heterologous DNA, wherein non-AAV vector DNA makes up less than 10% of the total amount of DNA in the particle.

### Claim 14 (depends on 13)

The rAAV particle of claim 13, wherein the rAAV particle is produced using a method of comprising culturing a cell comprising:
i) closed ended, linear duplex (CELiD) DNA comprising the heterologous DNA; and,
ii) one or more nucleic acid molecules encoding one or more AAV capsid (Cap) proteins;
under conditions suitable for formation of AAV particles containing the CELID DNA.

### Claim 15 (depends on 14)

The rAAV particle of claim 14, wherein the nucleic acid molecule(s) is/are stably inserted into the genome of the cell.

### Claim 16 (depends on 14)

The rAAV particle of claim 14, wherein the cultured cell comprises one or more polynucleotide molecules encoding one or more AAV Rep proteins, and wherein the culture conditions comprise a culture environment suitable for replication of the CELID DNA, expression of the one or more Cap proteins, and expression of the one or more Rep proteins.

### Claim 17 (depends on 14)

The rAAV of claim 14, wherein the cell is an invertebrate cell or a mammalian cell.

### Claim 18 (depends on 14)

The method of claim 14, wherein the heterologous DNA encodes a protein or a therapeutic RNA.

### Claim 19 (depends on 14)

The method of claim 14, wherein the therapeutic RNA comprises a siRNA, a RNAi, a shRNA, a miRNA, an aptamer, or a ribozyme.

### Claim 20

A method of producing closed ended, linear duplex (CELiD) DNA, comprising heterologous DNA, the method comprising:
a) culturing a cell comprising:
i) one or more polynucleotide sequences encoding one or more adeno-associated virus (AAV) Rep proteins; and,
ii) a nucleic acid molecule comprising heterologous DNA flanked by a pair of inverted terminal repeats (ITRs), wherein at least one ITR comprises an AAV Rep protein binding site and a AAV terminal resolution site (trs), and wherein at least one ITR can be used as an origin of replication;
under conditions suitable for replication of the nucleic acid molecule, thereby producing new CELiD DNA molecules; and
b) isolating the newly produced CELiD DNA molecules from the cell.

### Claim 21 (depends on 20)

The method of claim 20, wherein the nucleic acid molecule is CELiD DNA.
